1,338 reports of this reaction
4.7% of all CENEGERMIN BKBJ reports
#3 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #3 most commonly reported adverse reaction for CENEGERMIN BKBJ, manufactured by Domp farmaceutici S.p.A.. There are 1,338 FDA adverse event reports linking CENEGERMIN BKBJ to PRODUCT DOSE OMISSION ISSUE. This represents approximately 4.7% of all 28,659 adverse event reports for this drug.
Patients taking CENEGERMIN BKBJ who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is moderately reported among CENEGERMIN BKBJ users, representing a notable but not dominant share of adverse events.
In addition to product dose omission issue, the following adverse reactions have been reported for CENEGERMIN BKBJ:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 1,338 FDA reports for CENEGERMIN BKBJ. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 4.7% of all adverse event reports for CENEGERMIN BKBJ, making it one of the most commonly reported side effect.
If you experience product dose omission issue while taking CENEGERMIN BKBJ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.